Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 5/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | PNMT | P11086 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.44 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30218840 | 1.00 | CD44 (0.56) | CD44HTR2CHTR2AHTR2BPNMT | |
| Hydrochloric Acid SCHEMBL2260124 | 0.98 | CD44 (0.54) | CD44HTR2CHTR2AHTR2BPNMT | |
| SCHEMBL7639433 | 0.86 | CD44 (0.53) | CD44HTR2CHTR2AHTR2BPNMT | |
| SCHEMBL329629 | 0.86 | PNMT (0.56) | CD44HTR2CHTR2AHTR2BPNMT | |
| Hydrochloric Acid SCHEMBL2259424 | 0.84 | PNMT (0.54) | CD44HTR2CHTR2AHTR2BPNMT | |
| SCHEMBL8675324 | 0.83 | HTR2C (0.41) | CD44HTR2CHTR2AHTR2BPNMT | |
| SCHEMBL12903030 | 0.82 | CD44 (0.56) | CD44HTR2CPNMTMAOBPRCP | |
| Hydrochloric Acid SCHEMBL2657655 | 0.81 | HTR2C (0.40) | CD44HTR2CHTR2AHTR2BPNMT | |
| SCHEMBL11337766 | 0.79 | PNMT (0.46) | CD44HTR2CHTR2AHTR2BPNMT | |
| SCHEMBL16111166 | 0.79 | CD44 (0.53) | CD44HTR2CPNMTMAOBPRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112079775-B | Synthesis method of 5-trifluoromethyl isoquinoline-8-formic acid | 苏州康润医药有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-112079775-A | Synthesis method of 5-trifluoromethyl isoquinoline-8-formic acid | 苏州康润医药有限公司 | 2020-12-15 | — | — | CN | claimed |
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | ALKAHEST, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2024005526-A1 | NOVEL COMPOUND AS NADPH OXIDASE 2 INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 동국대학교 산학협력단 | 2024-01-04 | — | — | WO | disclosed |
| CN-112079775-B | Synthesis method of 5-trifluoromethyl isoquinoline-8-formic acid | 苏州康润医药有限公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-3194367-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR THE TREATMENT OF OBESITY AND DIABETES | BOEHRINGER INGELHEIM INT (DE) | 2021-08-18 | — | — | EP | disclosed |
| CN-112079775-A | Synthesis method of 5-trifluoromethyl isoquinoline-8-formic acid | 苏州康润医药有限公司 | 2020-12-15 | — | — | CN | disclosed |
| EP-2847193-B1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190031685-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-01-31 | — | — | US | disclosed |
| US-9951088-B2 | D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-2225223-B1 | ORGANIC COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2017-01-11 | — | — | EP | disclosed |
| EP-1501803-B1 | TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROISOQUINOLINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080188471-A1 | Dipeptidyl Peptidase-IV Inhibiting Compounds, Method Of Preparing The Same, And Pharmaceutical Compositions Containing The Same As An Active Agent | LG LIFE SCIENCES, LTD. (KR) | 2008-08-07 | — | — | US | disclosed |
| EP-1863812-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG Life Sciences Ltd. (KR) | 2007-12-12 | — | — | EP | disclosed |
| US-7166614-B2 | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166614-B2 | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2007-01-23 | — | — | US | disclosed |
| WO-2006104356-A1 | DIPEPTIDYL PEPTIDASE-IV INHIBITING COMPOUNDS, METHODS OF PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AS AN ACTIVE AGENT | LG LIFE SCIENCES, LTD. (KR) | 2006-10-05 | — | — | WO | disclosed |
| US-6465485-B1 | SUCH AS 7-CYANO-2-(2-(1-(4-(2-INDOLYL)CARBOXAMIDO)CYCLO-HEXYL)ETHYL)-1,2,3,4 -TETRAHYDROISOQUINOLINE; ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-15 | — | — | US | disclosed |
| EP-0983244-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050364-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188471-A1 | Dipeptidyl Peptidase-IV Inhibiting Compounds, Method Of Preparing The Same, And Pharmaceutical Compositions Containing The Same As An Active Agent | DPP4, DPP7, DPP8 | CD44 3437/4885HTR2C 4300/4885HTR2A 4033/4885 |
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | CCR3, CCR1, CCR4 | CD44 3691/4885HTR2C 3698/4885HTR2A 3808/4885 |
| US-20190031685-A1 | HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF | COMT, SNCA, KYNU | CD44 4730/4885HTR2C 11/4885HTR2A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.